Telesis Bio, Inc. – NASDAQ:TBIO
Telesis Bio stock price today
$0.022
-0.40
-94.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Telesis Bio stock price monthly change
-88.42%
month
Telesis Bio stock price quarterly change
-88.42%
quarter
Telesis Bio stock price yearly change
+9.25%
year
Telesis Bio key metrics
Market Cap | 834.64K |
Enterprise value | 1.09B |
P/E | -24.74 |
EV/Sales | 52.24 |
EV/EBITDA | -22.43 |
Price/Sales | 52.40 |
Price/Book | 20.68 |
PEG ratio | 0.23 |
EPS | -1.51 |
Revenue | 24.63M |
EBITDA | -29.50M |
Income | -45.24M |
Revenue Q/Q | -45.53% |
Revenue Y/Y | -12.38% |
Profit margin | -251.05% |
Oper. margin | -240.91% |
Gross margin | 47.67% |
EBIT margin | -240.91% |
EBITDA margin | -119.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTelesis Bio stock price history
Telesis Bio stock forecast
Telesis Bio financial statements
| Jun 2023 | 8.65M | -8.28M | -95.78% |
|---|---|---|---|
| Sep 2023 | 5.56M | -10.63M | -191.07% |
| Dec 2023 | 6.97M | -17.68M | -253.5% |
| Mar 2024 | 3.44M | -8.63M | -251.08% |
| 2025 | 37M | -319.99M | -864.84% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-08-09 | -0.48545 | -0.5 |
|---|---|---|
| 2022-11-08 | -0.3675 | -0.42 |
| 2023-03-21 | -0.41 | -0.28 |
| 2023-05-11 | -0.38 | -0.37 |
| Jun 2023 | 114526000 | 86.61M | 75.62% |
|---|---|---|---|
| Sep 2023 | 105029000 | 58.54M | 55.74% |
| Dec 2023 | 70411000 | 40.87M | 58.05% |
| Mar 2024 | 63331000 | 41.68M | 65.82% |
| Jun 2023 | -10.3M | 6.84M | 26.70M |
|---|---|---|---|
| Sep 2023 | -5.88M | -23.20M | -101K |
| Dec 2023 | -7.31M | 6.49M | -15.02M |
| Mar 2024 | -3.23M | 12.24M | -27K |
Telesis Bio alternative data
| Aug 2023 | 223 |
|---|---|
| Sep 2023 | 223 |
| Oct 2023 | 223 |
| Nov 2023 | 223 |
| Dec 2023 | 223 |
| Jan 2024 | 223 |
| Feb 2024 | 223 |
| Mar 2024 | 223 |
| Apr 2024 | 223 |
| May 2024 | 137 |
| Jun 2024 | 127 |
| Jul 2024 | 127 |
Telesis Bio other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2020 | 0 | 221666 |
| Sep 2021 | 71983597 | 3593617 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SUTHERLAND EVERETT RAND officer: President | Stock Option (right to buy) | 300,000 | $16.37 | $4,911,000 | ||
Sale | FORMELA JEAN FRANCOIS director | Stock Option (right to buy) | 2,055,063 | $10.2 | $20,961,643 | ||
Sale | BECKMAN DANIELLA director | Stock Option (right to buy) | 67,995 | $7.39 | $502,483 | ||
Sale | BURGESS PAUL D. officer: Chief Operating Office.. | Stock Option (right to buy) | 71,833 | $7.39 | $530,846 | ||
Sale | SMITH BRENDAN officer: Chief Financial Officer | Stcok Option (right to buy) | 201,800 | $19.23 | $3,880,614 | ||
Sale | RENAUD RONALD C JR director, officer: Chief Execut.. | Stock Option (right to buy) | 503,231 | $7.95 | $4,000,686 | ||
Sale | PLENGE ROBERT M director | Stock Option (right to buy) | 95,600 | $14.58 | $1,393,848 | ||
Sale | MEYER ROBERT J. director | Stock Option (right to buy) | 95,600 | $13.36 | $1,277,407 | ||
Sale | HUGHES OWEN director | Common Stock | 29,860 | $38 | $1,134,680 | ||
Sale | HUGHES OWEN director | Stock Option (right to buy) | 75,935 | $10.97 | $833,235 |
| Patent |
|---|
Grant Filling date: 15 May 2020 Issue date: 27 Sep 2022 |
Grant Filling date: 25 Sep 2020 Issue date: 20 Sep 2022 |
Grant Filling date: 5 Jan 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 10 Feb 2021 Issue date: 30 Aug 2022 |
Application Filling date: 11 Sep 2021 Issue date: 11 Aug 2022 |
Grant Filling date: 10 Nov 2017 Issue date: 2 Aug 2022 |
Application Filling date: 21 Apr 2020 Issue date: 28 Jul 2022 |
Application Filling date: 29 May 2020 Issue date: 21 Jul 2022 |
Application Filling date: 14 May 2020 Issue date: 14 Jul 2022 |
Grant Utility: mRNA therapy for phenylketonuria Filling date: 11 Jan 2019 Issue date: 5 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2023 11 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 25 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 12 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 14 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
What's the price of Telesis Bio stock today?
One share of Telesis Bio stock can currently be purchased for approximately $0.02.
-
When is Telesis Bio's next earnings date?
Unfortunately, Telesis Bio's (TBIO) next earnings date is currently unknown.
-
Does Telesis Bio pay dividends?
No, Telesis Bio does not pay dividends.
-
How much money does Telesis Bio make?
Telesis Bio has a market capitalization of 834.64K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 0.27% to 27.51M US dollars. Telesis Bio made a loss 47.72M US dollars in net income (profit) last year or -$0.37 on an earnings per share basis.
-
What is Telesis Bio's stock symbol?
Telesis Bio, Inc. is traded on the NASDAQ under the ticker symbol "TBIO".
-
What is Telesis Bio's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Telesis Bio?
Shares of Telesis Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Telesis Bio have?
As Jul 2024, Telesis Bio employs 127 workers, which is 43% less then previous quarter.
-
When Telesis Bio went public?
Telesis Bio, Inc. is publicly traded company for more then 4 years since IPO on 18 Jun 2021.
-
What is Telesis Bio's official website?
The official website for Telesis Bio is codexdna.com.
-
Where are Telesis Bio's headquarters?
Telesis Bio is headquartered at 29 Hartwell Ave, Lexington, MASSACHUSETTS.
-
How can i contact Telesis Bio?
Telesis Bio's mailing address is 29 Hartwell Ave, Lexington, MASSACHUSETTS and company can be reached via phone at +1 617 945 7361.
Telesis Bio company profile:
Telesis Bio, Inc.
codexdna.comExchange:
NASDAQ
Full time employees:
137
Industry:
Medical - Devices
Sector:
Healthcare
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
29 Hartwell Ave
Lexington, MASSACHUSETTS 92121-2993
Lexington, MASSACHUSETTS 92121-2993
CIK: 0001693415
ISIN: US1920031010
CUSIP: 89374L104
